What does the evidence say about Berberine Lipid Profile Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Berberine Lipid Profile Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - This review was based on a narrative literature search designed to identify experimental, clinical, and translational evidence linking natural products with gut barrier integrity, gut microbiota, low-grade inflammation, and metabolic endotoxemia. [Šantić Roko (2026); evidence level 3] - Because this article is a narrative review rather than a systematic review, formal risk-of-bias assessment and quantitative evidence synthesis were not performed. [Šantić Roko (2026); evidence level 3] - Over the past two decades, accumulating evidence has repositioned the gastrointestinal tract from a passive absorptive organ to an immunologically active barrier whose functional state directly influences systemic inflammatory tone and metabolic homeostasis []. [Šantić Roko (2026); evidence level 3] - Reference lists of relevant reviews and primary studies were additionally screened to identify articles not captured by database searches. [Šantić Roko (2026); evidence level 3] - Five strategies were analyzed for individuals with ASSIGN risk scores ≥20% and ≥10%: no intervention, atorvastatin 20 mg/day, berberine 1000 mg/day, simvastatin 20 mg plus berberine 1500 mg/day, and simvastatin 20 mg plus berberine 900 mg/day. [Xia Y (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.